Oxford Biomedica Ltd. engages in the biopharmaceutical business. It develops gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. It collaborates and develops novel targeted therapies and therapeutic vaccines to treat multiple types of cancer. Oxford Biomedica offers products, including prosavin, retinostat, stargen, ushstat, encorstat, monudin, trovax, targeted antibody therapy, hi-8 MEL, metXia and endoAngio-GT. Its technologies include lentiVector, 5T4 tumour antigen, Hi-8 primeboost, gene-directed enzyme prodrug therapy and anti-angiogenesis. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1995 and is headquartered in Oxford, the United Kingdom.